Results 11 to 20 of about 1,327 (186)

Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study) [PDF]

The Journal of Headache and Pain
Background Rimegepant, a novel oral calcitonin gene-related peptide receptor antagonist, has been recently approved for the acute migraine treatment. While its efficacy was confirmed in randomized clinical trials, no data is available regarding real-life
Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, Francesco Casillo, Antonio Russo, Marcello Silvestro, Francesca Pistoia, Giorgio Dalla Volta, Matteo Cortinovis, Alberto Chiarugi, Danilo Antonio Montisano, Maria Pia Prudenzano, Sabina Cevoli, Edoardo Mampreso, Gianluca Avino, Marina Romozzi, Mariarosaria Valente, Carla Fasano, Stefania Battistini, Antonio Granato, Elisa Maria Piella, Innocenzo Rainero, Raffaele Ornello, Roberto De Icco, On behalf of the Italian Headache Registry (RICe) Study Group   +24 more
doaj   +4 more sources

Use of rimegepant as an alternative to triptans in migraine treatment [PDF]

Quality in Sport
Introduction and aim of study: Migraine is a chronic neurological disorder that is considered one of the leading causes of disability worldwide. Increasing evidence indicates that the calcitonin gene-related peptide (CGRP), a neuropeptide released ...
Aleksandra Jaroń, Katarzyna Jastrzębska, Maria Witkowska, Joanna Skotnicka, Karolina Błaszczak, Monika Turek, Klara Wojciechowska, Adrian Borkowski, Mateusz Sawicki   +8 more
doaj   +4 more sources

Rimegepant - a breakthrough drug for migraine treatment - literature review [PDF]

Quality in Sport
Migraine is a chronic condition that manifests itself periodically. It is characterized by recurrent, severe, often hemiplegic, throbbing headaches accompanied by autonomic symptoms in the form of nausea, vomiting, hypersensitivity to noise and light ...
Katarzyna Kuleta, Julia Głoskowska, Agata Frańczuk, Michalina Grzelka, Aleksandra Makłowicz, Ewelina Kopczyńska, Angelika Szpulak, Patrycja Karkos, Katarzyna Kuśmierczyk, Natalia Dolata   +9 more
doaj   +6 more sources

Rimegepant for the treatment of migraine [PDF]

Health Psychology Research, 2022
Migraine is a common form of primary headache, affecting up to 1 in every 6 Americans. The pathophysiology is an intricate interplay of genetic factors and environmental influence and is still being elucidated in ongoing studies. The trigeminovascular system is now known to have a significant role in the initiation of migraines, including the release ...
Berger, Amnon A, Winnick, Ariel, Carroll, Austin H, Welschmeyer, Alexandra, Li, Nathan, Colon, Marc, Paladini, Antonella, Ramírez, Giovanni F, Hasoon, Jamal, Cornett, Elyse M, Song, Jaehong, Varrassi, Giustino, Kaye, Adam M, Kaye, Alan D, Ganti, Latha   +14 more
openaire   +7 more sources

Rimegepant: first novel oral calcitonin gene-related peptide inhibitor for migraine [PDF]

International Journal of Basic & Clinical Pharmacology, 2020
Migraine is a neurological condition characterized by intense, debilitating headaches. Symptoms may include nausea, vomiting, numbness or tingling, sensitivity to light and sound. There are multitude of drugs available to treat migraine like triptans, non-steroidal anti-inflammatory drugs, ergots and opioids. But these drugs are associated with adverse
Saravana Kumar Ramasubbu, Senkadhirdasan Dakshinamurthy, Sarika Palepu, Arkapal Bandyopadhyay, Sathish Kumar Rajendran   +4 more
openaire   +3 more sources

Population Pharmacokinetic Modeling of the Oral Calcitonin Gene‐Related Peptide Receptor Antagonist Rimegepant in Adults [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Rimegepant is a small‐molecule calcitonin gene‐related peptide receptor antagonist approved for acute and preventive migraine treatment in adults, administered as an orally disintegrating tablet (ODT).
Craig M. Comisar, Jim H. Hughes, Jose Francis, Yorinao Chinda, Yamato Sano, Chieko Muto, Christine Neumar, Rajinder Bhardwaj, Richard Bertz, Jing Liu   +9 more
doaj   +2 more sources

The efficacy of rimegepant for the acute treatment of vestibular migraine [PDF]

Scientific Reports
Introduction This study aimed to observe the efficacy and safety of rimegepant, a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of vestibular migraine (VM).
Heling Chu, Jingwei Pan, Chuyi Huang
doaj   +2 more sources

Treating Menière’s disease with rimegepant

Swiss Medical Weekly
A recent hypothesis states that Menière’s disease is caused by inappropriate expression, i.e. enhanced release of the neurotransmitter calcitonin gene-related peptide.
Stefan C. A. Hegemann, Angela Schell
doaj   +3 more sources

Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study

Cephalalgia Reports, 2022
Background: Rimegepant, a small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonist, is approved for the acute and preventive treatment of migraine. We hypothesized that intermittent CGRP receptor blockade with rimegepant 75 mg acute
Karissa M Johnston
exaly   +2 more sources

Rimegepant in airplane headache treatment: a case report. [PDF]

J Med Case Rep
Airplane headache is a rare condition first identified in 2004 and subsequently included in the International Classification of Headache Disorders (Headache Classification Committee of the International Headache Society in Cephalalgia 33:629-808, 2013. https://doi.org/10.1177/0333102413485658 ). Airplane headache typically presents as intense, stabbing,
Autunno M, De Luca M, Ferraù L, Rodolico C.   +3 more
europepmc   +5 more sources